Competitive Intelligence Dashboard
Novartis External View
Filter by Disease State
Priority Competitors
Pfizer
Merck
AstraZeneca
Roche
BMS
J&J
Recent Alerts
View AllPfizer granted priority review for new multiple myeloma therapy
High PriorityThe FDA has granted priority review for Pfizer's novel BCMA-targeted therapy for relapsed/refractory multiple myeloma. The PDUFA date is set for October 15, 2025.
Implications:
This priority review could accelerate Pfizer's entry into the multiple myeloma market with a potential approval 4 months ahead of schedule. If approved, this would be the third BCMA-targeted therapy on the market, increasing competition in this space.
Recommendations:
Consider accelerating development timelines for competing multiple myeloma assets. Prepare market access strategy to differentiate from Pfizer's offering.
AstraZeneca reports positive Phase 3 results for IL-13 inhibitor in severe asthma
Medium PriorityAstraZeneca announced positive topline results from their Phase 3 trial of their IL-13 inhibitor in severe asthma. The study met its primary endpoint of reduction in exacerbation rate.
BMS submits sNDA for psoriasis indication expansion
Low PriorityBristol Myers Squibb has submitted a supplemental New Drug Application (sNDA) to expand the indication of their IL-17 inhibitor to include moderate-to-severe plaque psoriasis in adolescents.
Data Snacks
View AllMultiple Myeloma Market Share Analysis
Analysis of Q1 2025 market share data for multiple myeloma therapies shows shifting dynamics with new entrants.
Psoriasis Patient Journey Insights
New research reveals key decision points in the psoriasis patient journey and opportunities for intervention.
Severe Asthma Prescriber Trends
Analysis of prescribing patterns for biologics in severe asthma shows increasing adoption among pulmonologists.
Pipeline Updates
View All| Company | Asset | Indication | Phase | Status | Last Update |
|---|---|---|---|---|---|
| Pfizer | PF-06863135 | Multiple Myeloma | Phase 3 | Active | May 28, 2025 |
| AstraZeneca | AZD-1402 | Severe Asthma | Phase 3 | Active | May 27, 2025 |
| BMS | BMS-986165 | Psoriasis (Adolescent) | Regulatory | Submitted | May 24, 2025 |
| Roche | RG-6234 | Multiple Myeloma | Phase 1 | New | May 26, 2025 |
Clinical Trials Updates
View AllNCT05123456
New TrialPfizer initiated a new Phase 3 trial for PF-06863135 in multiple myeloma patients who have received at least one prior line of therapy.
NCT05789012
Status ChangeAstraZeneca's Phase 3 trial for AZD-1402 in severe asthma has completed enrollment ahead of schedule.
Weekly Snapshot
View AllWeek of May 22-28, 2025
Key Highlights:
- Pfizer's BCMA-targeted therapy received priority review
- AstraZeneca reported positive Phase 3 results in severe asthma
- BMS submitted sNDA for adolescent psoriasis indication
Clinical Trial Updates:
- 2 new trials initiated (Multiple Myeloma, Psoriatic Arthritis)
- 1 trial completed enrollment (Severe Asthma)
- 1 trial reported topline results (Severe Asthma)
© 2025 CI Agent. All rights reserved.